# EDGAR Filing Document

**Accession Number:** 0001907108
**File Stem:** 0000000000-25-006429
**Filing Date:** 2025-6
**Character Count:** 3639
**Document Hash:** 1f0427f0c1f3b2d52ba6d6195e3a742c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006429.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0000000000-25-006429

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250618

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lexeo Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001907108
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 854012572
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288025

**BUSINESS ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 547-9879

**MAIL ADDRESS:**
- **STREET 1:** 345 PARK AVENUE SOUTH
- **STREET 2:** FLOOR 6
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-25-140744

## Text-Extract

```

                                                             June 18, 2025

R. Nolan Townsend
Chief Executive Officer
Lexeo Therapeutics, Inc.
345 Park Avenue South, Floor 6
New York, NY 10010

       Re: Lexeo Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed June 13, 2025
           File No. 333-288025
Dear R. Nolan Townsend:

       We have conducted a limited review of your registration statement and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-3
General

1.     In relation to the 20,840,394 shares of common stock underlying the
Warrant Shares
       issued in the Private Placement on May 28, 2025, please tell us your
basis for
       registering the offering of these shares on a primary basis. In this
regard, we note your
       disclosure on page 4 that the Warrant Shares were issued pursuant to
Section 4(a)(2)
       of the Securities Act, that each Selling Shareholder represented that
they were an
       "accredited investor" as defined in Regulation D of the Securities Act,
and that "[t]he
       Warrants are exercisable at any time," such that the Warrants are
exercisable within
       one year. Please consider the rationale set out in Securities Act
Sections C&DI
       Questions 103.04, 139.08 and 239.15.
 June 18, 2025
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Daniel Crawford at 202-551-7767 or Tim Buchmiller at
202-551-3635
with any other questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Megan J. Baier, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._